Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,110.40
(
-0.36%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.48
(
1.82%
)
Bitcoin
78,150.73
(
-0.11%
)
News Focus
News Focus
Post# of 648882
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 217
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: Tuff-Stuff post# 496511

Thursday, 01/31/2013 4:53:56 AM

Thursday, January 31, 2013 4:53:56 AM

Post# of 648882
Novo Nordisk (NVO): Q4 EPS of DKK10.53 beats by DKK0.77. Q4 EBIT +25% to DKK7.57B. Net profit +23% to DKK5.75B. Sales +16% to DKK20.96B. Sales of diabetes drug was driven by Victoza +29%, modern insulins +20%, NovoSeven +20%. Expects FY13 sales growth to be 8-11%, Operating profit growth to be approx. 10%

Concentrate, and ASK the 8-Ball!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today